AC Immune, a Swiss biotech developing therapies for Alzheimer's disease, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering.
The Lausanne, Switzerland-based company was founded in 2003 and booked $39 million in sales for the 12 months ended March 31, 2016. It plans to list on the Nasdaq under the symbol ACIU. AC Immune filed confidentially on August 28, 2015. Credit Suisse, Jefferies and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
